panadol menthol active 500 mg proszek do sporządzania roztworu doustnego
haleon poland sp. z o.o. - paracetamolum - proszek do sporządzania roztworu doustnego - 500 mg
aleric deslo active 0,5 mg/ml roztwór doustny
us pharmacia sp. z o.o. - desloratadinum - roztwór doustny - 0,5 mg/ml
aleric deslo active 2,5 mg tabletki ulegające rozpadowi w jamie ustnej
us pharmacia sp. z o.o. - desloratadinum - tabletki ulegające rozpadowi w jamie ustnej - 2,5 mg
aleric deslo active 5 mg tabletki ulegające rozpadowi w jamie ustnej
us pharmacia sp. z o.o. - desloratadinum - tabletki ulegające rozpadowi w jamie ustnej - 5 mg
choligrip menthol active 600 mg + 40 mg + 10 mg proszek do sporządzania roztworu doustnego
haleon poland sp. z o.o. - paracetamolum + acidum ascorbicum + phenylephrini hydrochloridum - proszek do sporządzania roztworu doustnego - 600 mg + 40 mg + 10 mg
amoxy active 697 mg/g proszek doustny
dopharma research b.v. - amoxicillinum trihydricum - proszek doustny - 697 mg/g - kura; świnia
aleric deslo active 5 mg tabletki powlekane
us pharmacia sp. z o.o. - desloratadinum - tabletki powlekane - 5 mg
cattlemarker ibr inactivated - emulsja do wstrzykiwań
zoetis polska sp. z o.o. - szczepionka przeciw zakaźnemu zapaleniu nosa i tchawicy (ibr), oraz okresu siewstwa wirusa w zakażeniach bohv-1, inaktywowana - emulsja do wstrzykiwań - - - bydło
amoxy active ctd 800 mg/g proszek do podania w wodzie do picia
dopharma research b.v. - amoxicillinum trihydricum - proszek do podania w wodzie do picia - 800 mg/g - indyk; kaczka; kura
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - wieprzowy - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.